Close Menu

NEW YORK – Cleveland Diagnostics said this week that its IsoPSA Assay for prostate cancer has received breakthrough device designation from the US Food and Drug Administration. The company has finished two multicenter clinical trials in the US, led by the Cleveland Clinic, comparing the diagnostic accuracy of IsoPSA with PSA. The results demonstrate that IsoPSA has superior performance in identifying patients with high-grade disease, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.